Compare OXSQ & STXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OXSQ | STXS |
|---|---|---|
| Founded | 2003 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.7M | 139.3M |
| IPO Year | 2003 | 2004 |
| Metric | OXSQ | STXS |
|---|---|---|
| Price | $1.29 | $1.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | ★ 1.1M | 449.0K |
| Earning Date | 11-03-2026 | 08-11-2026 |
| Dividend Yield | ★ 32.81% | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ 0.10 | N/A |
| Revenue | N/A | ★ $29,346,617.00 |
| Revenue This Year | N/A | $6.04 |
| Revenue Next Year | $10.39 | $33.01 |
| P/E Ratio | $12.80 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.05 | $1.22 |
| 52 Week High | $2.05 | $3.59 |
| Indicator | OXSQ | STXS |
|---|---|---|
| Relative Strength Index (RSI) | 38.06 | 37.01 |
| Support Level | $1.24 | N/A |
| Resistance Level | $1.96 | $1.98 |
| Average True Range (ATR) | 0.03 | 0.06 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 37.50 | 9.39 |
Oxford Square Capital Corp is a closed-end, non-diversified management investment company. Its investment objective is to maximize portfolio's total return. Its primary current focus is to seek an attractive risk-adjusted total return by investing in corporate debt securities and, to a lesser extent collateralized loan obligation (CLO) structured finance investments that own corporate debt securities. CLO investments may also include warehouse facilities, which are early-stage CLO vehicles intended to aggregate loans that may be used to form the basis of a traditional CLO vehicle. The company may also invest in publicly traded debt and/or equity securities.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems, Disposables, Royalty, and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.